Clarity Pharmaceuticals Ltd (ASX:CU6 – Get Free Report) insider Michelle Parker purchased 542,710 shares of the firm’s stock in a transaction that occurred on Wednesday, October 2nd. The stock was purchased at an average price of A$0.91 ($0.62) per share, for a total transaction of A$494,951.52 ($334,426.70).
Clarity Pharmaceuticals Price Performance
About Clarity Pharmaceuticals
Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults. Its lead product includes SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2.
See Also
- Five stocks we like better than Clarity Pharmaceuticals
- What is the Nasdaq? Complete Overview with History
- MercadoLibre Targets Double-Digit Upside with Argentina Boom
- Which Wall Street Analysts are the Most Accurate?
- Domino’s Pizza Stock Delivers: A Hot Buy for Growth Investors
- What is the S&P 500 and How It is Distinct from Other Indexes
- 3 Small-Cap Stocks Ready to Deliver Significant Growth
Receive News & Ratings for Clarity Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clarity Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
